FeesSafety
Pluang+

rToken markets hit $1.16B in spot trading for tokenized U.S. stocks over seven weeks

Protocol Fundamentals
08 Nov 2026, 20:19 WIB
Tokenpost
View Source
Neutral
rToken markets hit $1.16B in spot trading for tokenized U.S. stocks over seven weeks

From June 2 to July 19, 2026, rToken markets recorded $1.16 billion in cumulative spot trading volume for tokenized U.S. stock products. These rTokens provide economic exposure to underlying shares without granting ownership or voting rights. They can be transferred to crypto wallets and used in decentralized finance applications, with cash dividends settled separately, typically in USDT. This activity highlights growing interest in tokenized stock trading within the crypto space.

Bitget's rToken markets recorded $1.16 billion in cumulative spot trading volume for tokenized U.S. stock products from June 2 to July 19, 2026. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 09, 2026 01:02 WIB: out of 50 priced assets, 8 rose and 40 fell. Notable movers include EOS with a price of Rp12.649 and a 1-day change of +8.13%, Bitcoin Cash at Rp4.398.712 down 5.75%, and COTI at Rp167 down 5.52%, with typical hold times ranging from 69 to 122 days and varied Pluang order activity.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
3 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
3 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
4 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
4 hours ago
XRP tests $1.15 support amid a 7% weekly drop, with inflation data eyed for next market move.

XRP tests $1.15 support amid a 7% weekly drop, with inflation data eyed for next market move.

XRP has fallen about 7% this week, trading near a critical support level of $1.15 after failing to hold gains above $1.35 earlier. The cryptocurrency faces bearish technical signals and could drop further to $1.10 if it breaks below $1.15. Institutio...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App